Literature DB >> 33369189

Prevalence of Lynch syndrome in women with mismatch repair-deficient ovarian cancer.

Rachel Hodan1,2, Kerry Kingham1,2, Kristina Cotter2, Ann K Folkins3, Allison W Kurian1,4,5, James M Ford1,4,6, Teri Longacre3.   

Abstract

BACKGROUND: There are limited data on the prevalence of Lynch syndrome (LS) in women with primary ovarian cancer with mismatch repair deficiency (MMR-D) by immunohistochemistry (IHC).
MATERIALS AND METHODS: Three hundred and eight cases of primary ovarian, fallopian, and peritoneal cancer between January 2012 and December 2019 were evaluated for MMR-D by IHC. The incidence of LS in this cohort was evaluated.
RESULTS: MMR-D by IHC was identified in 16 of 308 (5.2%) (95% CI: 3.2%-8.3%) primary ovarian-related cancers. Most cases with MMR-D were endometrioid (n = 11, 68.7%); (95% CI: 44.2%-86.1%). MSH2/MSH6 protein loss was detected in eight cases (50.0%); (95% CI: 28.0%-72.0%) and MLH1/PMS2 protein loss was detected in four cases (25.0%); (95% CI: 9.7%-50.0%). MSH6 protein loss was detected in two cases (12.5%); (95% CI: 2.2%-37.3%) and PMS2 protein loss was detected in two cases (12.5%); (95% CI: 2.2%-37.3%). All four cases with MLH1/PMS2 protein loss had MLH1 promotor hypermethylation. All 12 women with ovarian cancer suggestive of LS underwent germline testing and 8 (66.6%); (95% CI: 38.8%-86.5%) were confirmed to have LS.
CONCLUSIONS: Most ovarian cancers with somatic MMR-D were confirmed to have LS in this cohort. Germline testing for LS in addition to BRCA1/2 for all women with an epithelial ovarian cancer would be efficient and would approach 100% sensitivity for identifying Lynch syndrome. Utilization of a multigene panel should also be considered, given the additional non-Lynch germline mutation identified in this cohort.
© 2020 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Lynch syndrome; germline; mismatch repair; ovarian cancer; universal tumor screening

Mesh:

Substances:

Year:  2020        PMID: 33369189      PMCID: PMC7897945          DOI: 10.1002/cam4.3688

Source DB:  PubMed          Journal:  Cancer Med        ISSN: 2045-7634            Impact factor:   4.452


  20 in total

1.  Genetic Testing and Results in a Population-Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients.

Authors:  Allison W Kurian; Kevin C Ward; Nadia Howlader; Dennis Deapen; Ann S Hamilton; Angela Mariotto; Daniel Miller; Lynne S Penberthy; Steven J Katz
Journal:  J Clin Oncol       Date:  2019-04-09       Impact factor: 44.544

2.  Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.

Authors:  Lindsey E Minion; Jill S Dolinsky; Dana M Chase; Charles L Dunlop; Elizabeth C Chao; Bradley J Monk
Journal:  Gynecol Oncol       Date:  2015-01-23       Impact factor: 5.482

3.  Germline pathogenic variants identified in women with ovarian tumors.

Authors:  Natalie J Carter; Megan L Marshall; Lisa R Susswein; Kristin K Zorn; Susan Hiraki; Kevin J Arvai; Rebecca I Torene; Anna K McGill; Lauren Yackowski; Patricia D Murphy; Zhixiong Xu; Benjamin D Solomon; Rachel T Klein; Kathleen S Hruska
Journal:  Gynecol Oncol       Date:  2018-10-12       Impact factor: 5.482

4.  Development of an MSI-positive colon tumor with aberrant DNA methylation in a PPAP patient.

Authors:  Kiyoshi Yamaguchi; Eigo Shimizu; Rui Yamaguchi; Seiya Imoto; Mitsuhiro Komura; Seira Hatakeyama; Rei Noguchi; Kiyoko Takane; Tsuneo Ikenoue; Yoshimasa Gohda; Hideaki Yano; Satoru Miyano; Yoichi Furukawa
Journal:  J Hum Genet       Date:  2019-05-14       Impact factor: 3.172

5.  Uncertainty in the utility of immunohistochemistry in mismatch repair protein expression in epithelial ovarian cancer.

Authors:  Domenico Coppola; Santo V Nicosia; Andrea Doty; Thomas A Sellers; Ji-Hyun Lee; Jimmy Fulp; Zachary Thompson; Sanja Galeb; John McLaughlin; Steven A Narod; Joellen Schildkraut; Tuya Pal
Journal:  Anticancer Res       Date:  2012-11       Impact factor: 2.480

6.  Association between IHC and MSI testing to identify mismatch repair-deficient patients with ovarian cancer.

Authors:  Ji-Hyun Lee; Deborah Cragun; Zachary Thompson; Domenico Coppola; Santo V Nicosia; Mohammad Akbari; Shiyu Zhang; John McLaughlin; Steven Narod; Joellen Schildkraut; Thomas A Sellers; Tuya Pal
Journal:  Genet Test Mol Biomarkers       Date:  2014-03-04

7.  Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer.

Authors:  Rebecca A Barnetson; Albert Tenesa; Susan M Farrington; Iain D Nicholl; Roseanne Cetnarskyj; Mary E Porteous; Harry Campbell; Malcolm G Dunlop
Journal:  N Engl J Med       Date:  2006-06-29       Impact factor: 91.245

8.  A mutation in POLE predisposing to a multi-tumour phenotype.

Authors:  Anna Rohlin; Theofanis Zagoras; Staffan Nilsson; Ulf Lundstam; Jan Wahlström; Leif Hultén; Tommy Martinsson; Göran B Karlsson; Margareta Nordling
Journal:  Int J Oncol       Date:  2014-04-29       Impact factor: 5.650

9.  Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer.

Authors:  T Pal; M R Akbari; P Sun; J-H Lee; J Fulp; Z Thompson; D Coppola; S Nicosia; T A Sellers; J McLaughlin; H A Risch; B Rosen; P Shaw; J Schildkraut; S A Narod
Journal:  Br J Cancer       Date:  2012-10-09       Impact factor: 7.640

10.  Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database.

Authors:  Mev Dominguez-Valentin; Julian R Sampson; Toni T Seppälä; Sanne W Ten Broeke; John-Paul Plazzer; Sigve Nakken; Christoph Engel; Stefan Aretz; Mark A Jenkins; Lone Sunde; Inge Bernstein; Gabriel Capella; Francesc Balaguer; Huw Thomas; D Gareth Evans; John Burn; Marc Greenblatt; Eivind Hovig; Wouter H de Vos Tot Nederveen Cappel; Rolf H Sijmons; Lucio Bertario; Maria Grazia Tibiletti; Giulia Martina Cavestro; Annika Lindblom; Adriana Della Valle; Francisco Lopez-Köstner; Nathan Gluck; Lior H Katz; Karl Heinimann; Carlos A Vaccaro; Reinhard Büttner; Heike Görgens; Elke Holinski-Feder; Monika Morak; Stefanie Holzapfel; Robert Hüneburg; Magnus von Knebel Doeberitz; Markus Loeffler; Nils Rahner; Hans K Schackert; Verena Steinke-Lange; Wolff Schmiegel; Deepak Vangala; Kirsi Pylvänäinen; Laura Renkonen-Sinisalo; John L Hopper; Aung Ko Win; Robert W Haile; Noralane M Lindor; Steven Gallinger; Loïc Le Marchand; Polly A Newcomb; Jane C Figueiredo; Stephen N Thibodeau; Karin Wadt; Christina Therkildsen; Henrik Okkels; Zohreh Ketabi; Leticia Moreira; Ariadna Sánchez; Miquel Serra-Burriel; Marta Pineda; Matilde Navarro; Ignacio Blanco; Kate Green; Fiona Lalloo; Emma J Crosbie; James Hill; Oliver G Denton; Ian M Frayling; Einar Andreas Rødland; Hans Vasen; Miriam Mints; Florencia Neffa; Patricia Esperon; Karin Alvarez; Revital Kariv; Guy Rosner; Tamara Alejandra Pinero; María Laura Gonzalez; Pablo Kalfayan; Douglas Tjandra; Ingrid M Winship; Finlay Macrae; Gabriela Möslein; Jukka-Pekka Mecklin; Maartje Nielsen; Pål Møller
Journal:  Genet Med       Date:  2019-07-24       Impact factor: 8.822

View more
  3 in total

1.  Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.

Authors:  Karolin Heinze; Tayyebeh M Nazeran; Sandra Lee; Pauline Krämer; Evan S Cairns; Derek S Chiu; Samuel Cy Leung; Eun Young Kang; Nicola S Meagher; Catherine J Kennedy; Jessica Boros; Friedrich Kommoss; Hans-Walter Vollert; Florian Heitz; Andreas du Bois; Philipp Harter; Marcel Grube; Bernhard Kraemer; Annette Staebler; Felix Kf Kommoss; Sabine Heublein; Hans-Peter Sinn; Naveena Singh; Angela Laslavic; Esther Elishaev; Alex Olawaiye; Kirsten Moysich; Francesmary Modugno; Raghwa Sharma; Alison H Brand; Paul R Harnett; Anna DeFazio; Renée T Fortner; Jan Lubinski; Marcin Lener; Aleksandra Tołoczko-Grabarek; Cezary Cybulski; Helena Gronwald; Jacek Gronwald; Penny Coulson; Mona A El-Bahrawy; Michael E Jones; Minouk J Schoemaker; Anthony J Swerdlow; Kylie L Gorringe; Ian Campbell; Linda Cook; Simon A Gayther; Michael E Carney; Yurii B Shvetsov; Brenda Y Hernandez; Lynne R Wilkens; Marc T Goodman; Constantina Mateoiu; Anna Linder; Karin Sundfeldt; Linda E Kelemen; Aleksandra Gentry-Maharaj; Martin Widschwendter; Usha Menon; Kelly L Bolton; Jennifer Alsop; Mitul Shah; Mercedes Jimenez-Linan; Paul Dp Pharoah; James D Brenton; Kara L Cushing-Haugen; Holly R Harris; Jennifer A Doherty; Blake Gilks; Prafull Ghatage; David G Huntsman; Gregg S Nelson; Anna V Tinker; Cheng-Han Lee; Ellen L Goode; Brad H Nelson; Susan J Ramus; Stefan Kommoss; Aline Talhouk; Martin Köbel; Michael S Anglesio
Journal:  J Pathol       Date:  2022-02-07       Impact factor: 9.883

Review 2.  Microsatellite Instability: From the Implementation of the Detection to a Prognostic and Predictive Role in Cancers.

Authors:  Martina Amato; Renato Franco; Gaetano Facchini; Raffaele Addeo; Fortunato Ciardiello; Massimiliano Berretta; Giulia Vita; Alessandro Sgambato; Sandro Pignata; Michele Caraglia; Marina Accardo; Federica Zito Marino
Journal:  Int J Mol Sci       Date:  2022-08-05       Impact factor: 6.208

3.  The prevalence of mismatch repair deficiency in ovarian cancer: A systematic review and meta-analysis.

Authors:  Amit Atwal; Tristan Snowsill; Marcus Cabrera Dandy; Thomas Krum; Claire Newton; Dafydd Gareth Evans; Emma J Crosbie; Neil A J Ryan
Journal:  Int J Cancer       Date:  2022-07-06       Impact factor: 7.316

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.